Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Multiple Myeloma
DRUG: Elranatamab
Incidence of nonserious adverse events (AEs) leading to permanent discontinuation, A minimum of 90 days after the last dose of study drug|Incidence of serious adverse events (SAEs), A minimum of 90 days after the last dose of study drug
This is a single-arm elranatamab post-trial access study. Participants will receive elranatamab. All participants will receive elranatamab until disease progression, unacceptable toxicity, withdrawal of consent, study termination or, elranatamab becomes commercially accessible in the participant's country.